Start Of Phase II Study For Cav2.2 Selective Blocker CNV2197944 In Pain Associated With Post-Herpetic Neuralgia
Wednesday, April 24, 2013 - 05:10
in Health & Medicine
Currently, 1.5 billion people worldwide report chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out, with approximately 3-4.5% of the global population affected, and incidence rate increasing in line with increased age of the population. According to a recent estimate, the global pain management market is to reach US$60 Billion by 2015.[1]Convergence Pharmaceuticals Limited has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. read more